Wuhan Healthgen Biotechnology Corp. (688765)

Overview

Wuhan Healthgen Biotechnology Corp. is an innovation-driven biopharmaceutical company focused on developing and producing plant-made pharmaceuticals. Utilizing its proprietary rice endosperm expression platform known as OryzHiExp, the company was established in 2006 and has since successfully pioneered the large-scale, animal-free production of recombinant proteins and peptides directly within rice grains. This innovative approach has led to a diverse portfolio of products that include crucial therapeutic proteins such as recombinant human serum albumin and alpha-1 antitrypsin, among others.

In response to the increasing demand for safer, plant-derived alternatives to blood plasma-sourced products, Healthgen is prioritizing its recombinant human albumin. Its lead product, a plant-derived recombinant human serum albumin injection, has completed phase 3 clinical trials and is poised to be the first of its kind to receive approval for use in China. Furthermore, Healthgen's platform supports a variety of applications across pharmaceuticals, life sciences research, cell culture, and cosmetics. It embodies important trends in biotechnology and synthetic biology, which emphasize scalable, cost-effective, and environmentally friendly biomanufacturing solutions. The company's distinct position in the growth tier of the Shanghai Stock Exchange's STAR Market highlights its contribution to China's technological advancement in the rapidly changing realm of plant-based biopharmaceuticals.

Products and Services

• Recombinant Human Serum Albumin

  This product aims to replace traditional human serum albumin sourced from blood plasma, providing a safer, plant-derived alternative. It is particularly important for various medical applications, ensuring a reliable option for healthcare providers.

• Alpha-1 Antitrypsin

  This therapeutic protein is essential for protecting the lungs and liver from damage. Healthgen’s plant-based version is designed to improve safety and efficacy in treating conditions associated with alpha-1 antitrypsin deficiency.

• Basic Fibroblast Growth Factor

  This growth factor plays a critical role in wound healing and tissue regeneration. Healthgen’s product offers a plant-derived option that can be utilized in regenerative medicine and other therapeutic applications.

• OryzHiExp Expression Platform

  This proprietary platform allows for the efficient and scalable production of recombinant proteins within rice grains, promoting environmentally sustainable practices in biomanufacturing and corresponding applications across various sectors.

• Research and Development Services

  Healthgen offers R&D services to collaborate on projects aimed at advancing plant-based biopharmaceutical technologies, focusing on innovation and improving the efficacy of biological therapeutics.

• Cell Culture Products

  The company provides cell culture media and supplements developed from its plant-based expression systems, enhancing the growth and productivity of cell lines used for research and industrial production.

• Cosmetic Applications

  With a focus on the beauty industry, Healthgen develops plant-derived compounds that can be incorporated into cosmetic formulations, promoting skin health with natural ingredients.